
Global & Belgium Cancer Therapeutics Market to 2031
Description
According to data from the Spanish Network of Cancer Registries, Belgium reported approximately 11,734 new breast cancer cases in November 2022. That year, breast cancer was responsible for 2,362 deaths in the country. The rising incidence of cancer is driving increased demand for effective cancer treatments. As more patients seek care, healthcare providers are in need of innovative therapies to address various cancer types. In June 2024, Belgium introduced an action plan focused on expanding access to cutting-edge cancer treatments, particularly radioligand therapy, also known as Targeted Radionuclide Therapy, which holds promise as a groundbreaking approach in cancer management.
Belgium also fosters strong research collaborations to advance cancer care. In April 2023, DeuterOncology, a biotech firm based in Liège, received the Win4Company grant from Service Public de Wallonie (SPW) Recherche, totaling US$ 0.53 million (0.47 million EUR). This funding supported a partnership with Radiomics, another Liège-based biotech company, to combine their expertise in developing and validating an AI-driven imaging biomarker. This biomarker aims to serve as a companion diagnostic for DeuterOncology’s novel best-in-class deuterated MET kinase inhibitor (DO-2). Such innovative biomarkers are expected to enhance the personalization and optimization of cancer therapies. This collaboration brings together two Belgian biotech companies focused on identifying lung cancer patient subsets with MET gene alterations.
Belgium also fosters strong research collaborations to advance cancer care. In April 2023, DeuterOncology, a biotech firm based in Liège, received the Win4Company grant from Service Public de Wallonie (SPW) Recherche, totaling US$ 0.53 million (0.47 million EUR). This funding supported a partnership with Radiomics, another Liège-based biotech company, to combine their expertise in developing and validating an AI-driven imaging biomarker. This biomarker aims to serve as a companion diagnostic for DeuterOncology’s novel best-in-class deuterated MET kinase inhibitor (DO-2). Such innovative biomarkers are expected to enhance the personalization and optimization of cancer therapies. This collaboration brings together two Belgian biotech companies focused on identifying lung cancer patient subsets with MET gene alterations.
Table of Contents
100 Pages
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Data Triangulation and Validation:
- 4. Belgium Cancer Therapeutics Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 5. Cancer Therapeutics Market Key Market Dynamics
- 5.1 Cancer Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints
- 6. Belgium Cancer Therapeutics Market – Analysis
- 6.1 Belgium Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 Belgium Cancer Therapeutics Market Revenue and Forecast Analysis
- 7. Belgium Cancer Therapeutics Market Analysis – by Therapy Types
- 7.1 Belgium Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
- 8. Belgium Cancer Therapeutics Market Analysis – by Indications
- 8.1 Belgium Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
- 9. Belgium Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 Belgium Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
- 10. Competitive Landscape
- 10.1 Heat Map Analysis by Key Players
- 10.1 Company Positioning and Concentration
- 11. Industry Landscape
- 11.1 Overview
- 11.2 Market Initiative
- 11.2 Partnerships and Collaborations
- 11.2 Other Developments
- 12. Company Profiles
- 12.1 Bristol-Myers Squibb Co
- 12.1. 1 Key Facts
- 12.1. 2 Business Description
- 12.1. 3 Products and Services
- 12.1. 4 Financial Overview
- 12.1. 5 SWOT Analysis
- 12.1. 6 Key Developments
- 12.2 AbbVie Inc
- 12.2. 1 Key Facts
- 12.2. 2 Business Description
- 12.2. 3 Products and Services
- 12.2. 4 Financial Overview
- 12.2. 5 SWOT Analysis
- 12.2. 6 Key Developments
- 12.3 Johnson & Johnson
- 12.3. 1 Key Facts
- 12.3. 2 Business Description
- 12.3. 3 Products and Services
- 12.3. 4 Financial Overview
- 12.3. 5 SWOT Analysis
- 12.3. 6 Key Developments
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4. 1 Key Facts
- 12.4. 2 Business Description
- 12.4. 3 Products and Services
- 12.4. 4 Financial Overview
- 12.4. 5 SWOT Analysis
- 12.4. 6 Key Developments
- 12.5 Pfizer Inc
- 12.5. 1 Key Facts
- 12.5. 2 Business Description
- 12.5. 3 Products and Services
- 12.5. 4 Financial Overview
- 12.5. 5 SWOT Analysis
- 12.5. 6 Key Developments
- 12.6 AstraZeneca Plc
- 12.6. 1 Key Facts
- 12.6. 2 Business Description
- 12.6. 3 Products and Services
- 12.6. 4 Financial Overview
- 12.6. 5 SWOT Analysis
- 12.6. 6 Key Developments
- 12.7 Merck KGaA
- 12.7. 1 Key Facts
- 12.7. 2 Business Description
- 12.7. 3 Products and Services
- 12.7. 4 Financial Overview
- 12.7. 5 SWOT Analysis
- 12.7. 6 Key Developments
- 12.8 Novartis AG
- 12.8. 1 Key Facts
- 12.8. 2 Business Description
- 12.8. 3 Products and Services
- 12.8. 4 Financial Overview
- 12.8. 5 SWOT Analysis
- 12.8. 6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9. 1 Key Facts
- 12.9. 2 Business Description
- 12.9. 3 Products and Services
- 12.9. 4 Financial Overview
- 12.9. 5 SWOT Analysis
- 12.9. 6 Key Developments
- 12.10 Eli Lilly and Co
- 12.10. 1 Key Facts
- 12.10. 2 Business Description
- 12.10. 3 Products and Services
- 12.10. 4 Financial Overview
- 12.10. 5 SWOT Analysis
- 12.10. 6 Key Developments
- 13. Appendix
- 13.1 About Business Market Insights
- 13.2 List of Abbreviations
- TABLE OF TABLES
- Table 1. Belgium Cancer Therapeutics Market Segmentation
- Table 2. List of Vendors
- Table 3. Belgium Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
- Table 4. Belgium Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
- Table 5. Belgium Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
- Table 6. Belgium Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
- Table 7. Belgium Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
- Table 8. Belgium Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
- Table 9. Belgium Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
- Table 10. Belgium Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
- Table 11. List of Abbreviations
- TABLE OF FIGURES
- Figure 1. Impact Analysis of Drivers and Restraints
- Figure 2. Belgium Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
- Figure 3. Heat Map Analysis by Key Players
- Figure 4. Company Positioning and Concentration
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.